Product Name: CXXC4 Antibody
Species Reactivity: Human, Mouse, Rat
Tested Applications: ELISA, IF, IHC-P, WB
Applications: CXXC4 antibody can be used for detection of CXXC4 by Western blot at 1 μg/mL. Antibody can also be used for immunohistochemistry starting at 10 μg/mL. For immunofluorescence start at 20 μg/mL.
User Note: Optimal dilutions for each application to be determined by the researcher.
Predicted Molecular Weight:
Immunogen: CXXC4 antibody was raised against an 18 amino acid synthetic peptide near the amino terminus of human CXXC4.The immunogen is located within amino acids 50 – 100 of CXXC4.
Host Species: Rabbit
Purification: CXXC4 Antibody is affinity chromatography purified via peptide column.
Physical State: Liquid
CAS NO.: 2752-65-0
Product: Gambogic Acid
Buffer: CXXC4 Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration: 1 mg/mL
Storage Conditions: CXXC4 antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Clonality: Polyclonal
Conjugate: Unconjugated
Alternate Names: CXXC4 Antibody: IDAX, IDAX, CXXC-type zinc finger protein 4, Inhibition of the Dvl and axin complex protein
Accession NO.: NP_079488
Protein Ino: 13376816
Official Symbol: CXXC4
Geneid: 80319
Background: CXXC4 Antibody: CXXC4 is zinc finger protein that binds directly to the PDZ domain of DVL1, a protein involved in the Wnt signaling pathway, through its C-terminal region. CXXC4s interaction with DVL1 competes with DVL1-AXIN binding, although the affinity of DVL1 for CXXC4 is lower than that for AXIN. In mouse fibroblasts, CXXC4 suppressed Wnt3a induction of beta-catenin and inhibited Wnt3a-dependent TCF4 activation, suggesting that CXXC4 acts as a negative regulator of the Wnt signaling pathway and functions between DVL and beta-catenin. Recent reports suggest that decreased CXXC4 expression is associated with kidney cancer metastasis, cell proliferation, reduced apoptosis in response to cancer drugs, and upregulation of genes involved with proliferation, invasion and cell survival, suggesting that CXXC4 plays a critical role in tumor progression in kidney cancer.
PubMed ID:http://aac.asm.org/content/37/9/1909.abstract
